{
    "abstract": "Fibrinolysis is a natural process that ensures blood fluidity through the removal of fibrin deposits. However, excessive fibrinolytic activity can lead to complications in different circumstances, such as general surgery or severe trauma. The current antifibrinolytic drugs in the market, aminocaproic acid (EACA) and tranexamic acid (TXA), require high doses repetitively to maintain their therapeutic effect. These high doses are related to a number of side effects such as headaches, nasal symptoms, or gastrointestinal discomfort and severely limit their use in patients with renal impairment. Therefore, the discovery of novel antifibrinolytics with a higher specificity and lower dosage could vastly improve the applicability of these drugs. Herein, we synthesized a total of ten compounds consisting of a combination of three key moieties: an oxadiazolone, a triazole, and a terminal amine. The IC",
    "authors": [
        {
            "affiliation": "IQS School of Engineering, Universitat Ramon Llull, Via Augusta 390, 08017 Barcelona, Spain.\nInstitute of Medical Engineering and Science, Massachusetts Institute of Technology, 77 Massachusetts Ave, Cambridge, MA 02139, USA.",
            "firstname": "Oriol",
            "initials": "O",
            "lastname": "Bosch-Sanz"
        },
        {
            "affiliation": "IQS School of Engineering, Universitat Ramon Llull, Via Augusta 390, 08017 Barcelona, Spain.",
            "firstname": "Yvette",
            "initials": "Y",
            "lastname": "Rabad\u00e0"
        },
        {
            "affiliation": "Laboratory of Biochemistry, Institut Qu\u00edmic de Sarri\u00e0, Universitat Ramon Llull, Via Augusta 390, 08017 Barcelona, Spain.",
            "firstname": "Xevi",
            "initials": "X",
            "lastname": "Biarn\u00e9s"
        },
        {
            "affiliation": "Institute of Medical Engineering and Science, Massachusetts Institute of Technology, 77 Massachusetts Ave, Cambridge, MA 02139, USA.\nAlxerion Biotech, 245 First St, Riverview II, 18th Floor, Cambridge, MA 02142, USA.",
            "firstname": "Javier",
            "initials": "J",
            "lastname": "Pedre\u00f1o"
        },
        {
            "affiliation": "Alxerion Biotech, 245 First St, Riverview II, 18th Floor, Cambridge, MA 02142, USA.",
            "firstname": "Luis",
            "initials": "L",
            "lastname": "Caveda"
        },
        {
            "affiliation": "IQS School of Engineering, Universitat Ramon Llull, Via Augusta 390, 08017 Barcelona, Spain.\nInstitute of Medical Engineering and Science, Massachusetts Institute of Technology, 77 Massachusetts Ave, Cambridge, MA 02139, USA.",
            "firstname": "Mercedes",
            "initials": "M",
            "lastname": "Balcells"
        },
        {
            "affiliation": "IQS School of Engineering, Universitat Ramon Llull, Via Augusta 390, 08017 Barcelona, Spain.",
            "firstname": "Jordi",
            "initials": "J",
            "lastname": "Martorell"
        },
        {
            "affiliation": "IQS School of Engineering, Universitat Ramon Llull, Via Augusta 390, 08017 Barcelona, Spain.\nGrup d'Enginyeria de Materials, Institut Qu\u00edmic de Sarri\u00e0, Universitat Ramon Llull, Via Augusta 390, 08017 Barcelona, Spain.",
            "firstname": "David",
            "initials": "D",
            "lastname": "S\u00e1nchez-Garc\u00eda"
        }
    ],
    "conclusions": null,
    "copyrights": null,
    "doi": "10.3390/ijms232314942\n10.1111/j.1365-2141.2005.05444.x\n10.1378/chest.124.3_suppl.33S\n10.1055/s-0037-1613567\n10.1177/0192623310389474\n10.1016/j.blre.2014.09.003\n10.1136/bmj.2.5809.311\n10.1111/bjh.15073\n10.1016/S0049-3848(97)00004-2\n10.1034/j.1399-6576.2002.461007.x\n10.1111/jth.12078\n10.1097/TA.0000000000000292\n10.1016/S0140-6736(10)60835-5\n10.1186/s13054-016-1265-x\n10.1172/JCI103885\n10.2165/00003495-199957060-00017\n10.1111/anae.12910\n10.1186/s13054-016-1322-5\n10.1213/00000539-200007000-00006\n10.2106/JBJS.L.00008\n10.1016/S0021-9258(17)34189-3\n10.1021/bi9521351\n10.1111/j.1432-1033.1980.tb04461.x\n10.1016/S0021-9258(18)32614-0\n10.1111/j.1600-0609.1965.tb01300.x\n10.1056/NEJMoa0802395\n10.1001/jama.297.5.471\n10.1021/jm301818g\n10.1016/S0165-6147(00)89058-6\n10.1021/jm701562x\n10.1021/ml400526d\n10.1021/acs.jmedchem.9b01060\n10.1021/acs.jmedchem.6b01474\n10.2174/1389557517666170127121215\n10.2174/1389557518666180524112050\n10.3390/molecules23123361\n10.1002/asia.201100432\n10.1016/j.ejmech.2019.111700\n10.1016/j.bmc.2019.07.005\n10.1021/acs.jcim.7b00255\n10.1016/j.bmcl.2009.04.134\n10.1016/0263-7855(96)00018-5\n10.1107/S0907444904011679\n10.1109/38.310720",
    "journal": "International journal of molecular sciences",
    "keywords": [
        "antifibrinolytic",
        "fibrinolysis",
        "oxadiazolone",
        "plasmin",
        "plasminogen",
        "tPa",
        "triazole"
    ],
    "methods": null,
    "publication_date": "2022-12-12",
    "pubmed_id": "36499270\n15842654\n12624622\n12970122\n12669114\n21119054\n25294122\n4553818\n29318575\n9058494\n12421192\n23176206\n25058244\n20554319\n27072503\n13664784\n10400410\n25440395\n27176727\n10866882\n24875032\n762124\n8611560\n6244956\n6833255\n5221699\n5834403\n18480196\n17284697\n23521080\n7482994\n18651727\n24900876\n31658420\n27976897\n28137242\n29792145\n30567416\n21954075\n31546197\n31300317\n28653850\n19464891\n8744570\n15272157",
    "results": null,
    "title": "1,2,3-Triazole Derivatives as Novel Antifibrinolytic Drugs.",
    "xml": "<Element 'PubmedArticle' at 0x788506b5eb10>"
}